© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.
September 21, 2021
No significant difference in mortality or stroke at 30 days or 1 year was seen in patients who underwent TAVR for bicuspid or tricuspid aortic stenosis.
September 20, 2021
A total of 269 participants were considered potentially overtreated, while 109 participants were appropriately on target, and 56 participants potentially undertreated.
September 17, 2021
The potential number of adults projected to be newly eligible for treatment had a range from 643,161 (LVEF, 41% - 50%) to 1,838,756 (LVEF, 41% - 60%).
September 08, 2021
Overall positive genetic test results for variants was 10.1% for patients diagnosed with AF before 66 years of age and 16.8% in patients diagnosed before 30 years of age.
September 02, 2021
Intensive systolic blood pressure control led to a large absolute difference in death and HF among patients with abnormal biomarker levels of hscTnT and NTproBNP.
August 31, 2021
Data show the outcome of all-cause mortality, MI, or stent thrombosis occurred in 5.3% of patients vaccinated against the flu and 7.2% of patients who were given placebo.
Investigators observed systolic blood pressure was lower by a rate of 6.9 mm Hg in the intervention group versus the control group.
Data show substantially reductions in cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death following fixed-dose combination treatment strategies.
August 30, 2021
Data show lower incidence of CV events following intensive treatment with a systolic blood pressure target of 110 to 130 mm Hg compared to standard treatment.
Data show oral anticoagulation following atrial fibrillation screening was initiated in 1036 participants, with 445 (29.7%) in the ILR group versus 591 (13.1%) in the control group.